Overview

Determine Effect of Enzalutamide (MDV3100) on the Androgen Signaling Pathway in Correlation With the Anti-tumor Effects of Enzalutamide

Status:
Completed

Trial end date:
2013-08-31

Target enrollment:

Participant gender:

Summary

This study is being conducted to determine the effect of enzalutamide on the androgen signaling pathway in correlation with the anti-tumor effects of enzalutamide to identify potential predictors of response or resistance to therapy.

Phase:

Phase 2

Details

Lead Sponsor:

Medivation, Inc.
Pfizer

Collaborators:

Astellas Pharma Inc
Medivation LLC, a wholly owned subsidiary of Pfizer Inc.